PMV Pharmaceuticals (PMVP) Stock Statistics & Valuation Metrics

PMV Pharmaceuticals has a market cap or net worth of $83.19M. The enterprise value is $45.86M.

PMV Pharmaceuticals has 53,329,390 shares outstanding. The number of shares has decreased by -2.65% in one year.

PMV Pharmaceuticals’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -79.45%.

The current PE Ratio of PMV Pharmaceuticals is ―. PMV Pharmaceuticals’s PEG ratio is -0.03.

In the last 12 months, PMV Pharmaceuticals had revenue of 0.00 and earned -77.74M in profits. Earnings per share was -1.48.

In the last 12 months, operating cash flow was -73.58M and capital expenditures -29.00K, giving a free cash flow of -73.61M billion.

PMV Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

PMV Pharmaceuticals upcoming earnings date is May 8, 2026, Before Open (Confirmed).

PMV Pharmaceuticals as a current ratio of 10.09, with Debt / Equity ratio of 0.80%

In the past 12 months, PMV Pharmaceuticals has paid -2.17M in taxes.

PMV Pharmaceuticals EV to EBITDA ratio is -0.33, with an EV/FCF ratio of -0.39.

PMV Pharmaceuticals has $112.94M in cash and marketable securities with $838.00K in debt, giving a net cash position of $112.11M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for PMV Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―